europass



Elisa Tassinari

Date of birth: 27/04/1995 | **Nationality:** Italian | **Gender:** Female | **Phone number:** (+39) 0543739975 (Work) | **Email address:** elisa.tassinari@irst.emr.it |

Address: Piero Maroncelli 40, Street, 47014, Meldola (Forlì), Italy (Work)

EDUCATION AND TRAINING

MEDICAL ONCOLOGIST (MD)

Medical Oncologist specialized in genitourinary cancers, with dedicated clinical experience and active involvement in clinical research. Participation in clinical trials and research activities focused on improving outcomes for patients with GU malignancies.

26/01/2021 – 06/02/2026 Bologna, Italy
RESIDENCY IN MEDICAL ONCOLOGY University of Bologna - Alma Mater Studiorum

Address Giuseppe Massarenti, 9 , 40138, Bologna, Italy | **Final grade** 110L/110 (Magna cum Laude) |

Thesis DYNAMIC CHANGES IN TUMOR MICROENVIRONMENT AND BIOMARKER EXPRESSION IN MUSCLE-INVASIVE BLADDER CANCER ACROSS NEOADJUVANT CHEMOTHERAPY: A COMBINED BRIGHT-FIELD AND STANDARD IMMUNOHISTOCHEMISTRY EVALUATION IN PAIRED TURBT–CYSTECTOMY SPECIMENS.

04/06/2020 Bologna, Italy
MEDICAL DEGREE University of Bologna - Alma Mater Studiorum

Address Giuseppe Massarenti, 9, 40138, Bologna, Italy | **Field of study** Medical Oncology | **Final grade** 110L/110 (Magna cum Laude) |

Thesis "Prognostic and Predictive factors of metastatic renal cell carcinoma in the immune-checkpoint inhibitors age"

WORK EXPERIENCE

MEDICAL ONCOLOGIST (MD) – IRST IRCCS "ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI, DINO AMADORI" – 07/02/2026 – Current – MELDOLA, FORLÌ, ITALY

Medical Oncologist with autonomous clinical responsibility in outpatient, Day Hospital and inpatient settings, with dedicated focus on genitourinary malignancies.

- Expertise in clinical assessment, staging, and delivery of systemic anticancer therapies (chemotherapy, immunotherapy, targeted therapies, ADCs), including management of treatment-related toxicities and oncologic emergencies.
- Active member of multidisciplinary tumor boards contributing to evidence-based treatment decision-making.
- Strong involvement in clinical research, including participation in clinical trials, development of research projects, data analysis, and contribution to scientific publications in the field of genitourinary oncology.

MEDICAL DOCTOR – IRST IRCCS "ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI, DINO AMADORI" – 07/07/2025 – 06/02/2026 – MELDOLA, FORLÌ, ITALY

Final-year Medical Oncology resident with a strong clinical and research focus on genitourinary malignancies, experienced in clinical data analysis, translational research, and guideline-based patient management. Main activities:

- Management of patients with genitourinary cancers
- Administration and monitoring of chemotherapy, immunotherapy, targeted therapies, and ADCs
- Participation in multidisciplinary tumor boards (MDT)
- Clinical trial patient screening and follow-up
- Toxicity management and supportive care

DOCTOR – AUSL BOLOGNA – 11/04/2022 – 06/05/2022 – BOLOGNA, ITALY

Activities related to the vaccine delivery plan during Sars-Cov-2 coronavirus Pandemic

DOCTOR – AUSL ROMAGNA - PUBLIC HEALTH UNIT – 16/11/2020 – 19/12/2020 – FORLÌ, ITALY

Activities to ensure the proper functioning of the Contact Tracing system during Sars-Cov-2 coronavirus Pandemic

SUB INVESTIGATOR IN CLINICAL TRIALS

01/08/2025 – CURRENT
C2321014 - MEVPRO-1 - A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE for study site 1104.

29/09/2025 – CURRENT
C2321003 - MEVPRO-2 - A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER for study site 1196.

13/10/2025 – CURRENT
CA017-078 : A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer, for study site 0193.

25/11/2025 – CURRENT
C5731001 - SGNDV-001 - KEYNOTE-D74 - An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)

30/12/2025 – CURRENT
MK-6482-011 - An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

08/06/2026 – CURRENT
LITESPARK-034 "A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination"

01/05/2026 – CURRENT
MEVPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

02/03/2026 – CURRENT
MK-5684-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA

02/03/2026 – CURRENT
MK-5684-003: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (OMAHA-003)

LANGUAGE SKILLS

Mother tongue(s): **ITALIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	B2	B2	B2	B2	B2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

CERTIFICATIONS

25/07/2025
ICH GOOD CLINICAL PRACTICE E6(R3)

ACLS, 08/10/2025
ADVANCED CARDIOVASCULAR LIFE SUPPORT

SCIENTIFIC ASSOCIATION MEMBERSHIP

ESMO - European Society of Medical Oncology

AIOM (Italian Association of Medical Oncology)

SKILLS

Excellent knowledge of Microsoft Windows and Apple Mac systems

Microsoft Office | Apple Mac systems

Good searching skills on scientific databases (PubMed, Scopus, NCBI, Google Scholar)

PubMed | Scopus

CONFERENCES AND SEMINARS

11/06/2026 Ancona
LE NEOPLASIE DEL TRATTO GENITOURINARIO NEL 2026 STATO DELL'ARTE E PROSPETTIVE FUTURE

18/05/2026 Bologna
Safety nel paziente in trattamento con Immunoterapia: Gestione IrAE e confronto con gli specialisti d'organo

06/05/2026 – 07/05/2026 Macerata
2^ ARON Meeting

28/11/2025 – 28/11/2025 Modena
Renal Cell Carcinoma (RCC) Preceptorship Sharing experience in treatment of RCC

06/03/2026 – 07/03/2026 Zurich, Switzerland
ESMO Advanced Course: Management of Patients with Localised Bladder Cancer: State-of-the-Art Therapeutic Strategies and Ongoing Research

25/10/2025 – 25/10/2025 Pavia
20 years of IGG - Italian Germ Cell Cancer Group

26/09/2025 – 26/09/2025 Meldola
Hot topics in the managment of patients with Prostate Cancer

23/05/2025 – 23/05/2025 Bologna
ARON meeting

15/04/2025 – 15/04/2025 Bologna
EXPANDING THE EXPERIENCE - Therapeutic strategies in GU Oncology

10/04/2025 – 11/04/2025 Castelfranco Veneto
ADVANCED URO ONCOLOGY DAYS

02/04/2025 – 03/04/2025 Naples
Onconnect - The role of communication in GU Oncology

16/01/2025 Bologna
Metastatic Renal Carcinoma: new therapeutic options

14/12/2024 – 14/12/2024 Milan
Joint Summit of International Bladder Cancer Group (IBCG) & the Global Society of rare Genitourinary Tumors (GSRGT)

13/12/2024 – 13/12/2024 Milan
SAN RAFFAELE UROLOGIC ONCOLOGY RETREAT (3rd edition 2024) Milano

24/10/2024 – 25/10/2024 Castellammare di Stabia
The Top Ten Italian Priorities in Renal Cell Carcinoma

13/09/2024 – 17/09/2024 Barcelona
ESMO Annual Congress

11/07/2023 Bologna
How does treatment algorithm change in CRC and mGC: sharing therapeutic strategies in the Oncology Network in Emilia-Romagna

03/04/2024 – 04/04/2024 Lugano
ESMO Preceptorship on Metastatic Bladder and Kidney Cancer

Oral presenter for the section "Focus on toxicities and duration of therapy" of the clinical case: "Multidisciplinary management of overlapping hepatotoxicity in a patient with mccRCCduring first-line immuno-based treatment"

14/12/2023 – 16/12/2023 Genoa (Online Webinar)
GRANDANGOLO 2023. A year of Medical Oncology

16/11/2023 – 18/11/2023 Riccione
XXX National Congress of SICP (Italian Society of Palliative Care)

10/11/2023 – 12/11/2023 Rome
XXV National Congress AIOM (Association of Italian Medical Oncology)

20/04/2023 – 21/04/2023 Castelfranco Veneto
Advanced Uro-Oncology 2023

15/12/2022 – 16/12/2022 Genoa
GRANDANGOLO 2022 - A year of Medical Oncology - XXIV edition

27/09/2022 Webinar
The treatment evolution of metastatic renal cell carcinoma and urothelial cancers. The experience in Emilia-Romagna

23/09/2022 – 24/09/2022 Bologna
Testicular Cancer - State of the art and future perspective

22/09/2022 Ravenna
Changing the rules advanced Bladder & Urothelial cancer

21/09/2022 Genoa
Young to Young 2022 - Tomorrow's Oncology

12/06/2022 – 13/06/2022 Webinar
COMU (Panel of Italian Medical Oncologists) summarize and comment on Chicago 2022 - The evolution of knowledge in Medical Oncology

07/06/2022 Bologna
m-BRaCe - The future treatment for patient with mCRPC and BRCA mutations

27/05/2022 Bologna
Focus on nmCRPC

04/03/2022 – 05/03/2022 Verbania
Onco-Young GU 2022

06/12/2021 – 14/02/2022 Webinar
Blended Learning for Immuno-Oncologists 2.0

PUBLICATIONS

2026
Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives.

Giunta EF, Schepisi G, Bleve S, et al. Discov Oncol. 2026 Feb 14. Epub ahead of print. PMID: 41689691.

2025
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes

Tassinari E, Danielli L, Marchetti A, et al. Hum Vaccin Immunother. 2025;21(1):2440165.

2025
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era?

Marchetti A, Mollica V, Brocchi S, et al. Expert Rev Mol Diagn. 2025 Apr;25(4): 91-93. Epub 2025 Feb 18.

2025
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean?

Rosellini M, Tassinari E, Danielli L, et al. Expert Rev Mol Diagn. 2025 Mar 12:1-4. Epub ahead of print.

2025
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges

Danielli L, Tassinari E, Marchetti A, et al. Expert Rev Anticancer Ther. Published online March 20, 2025.

2025
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single center experience

Rosellini M, Mollica V, Marchetti A, et al. Pathol Res Pract. Published online April 9, 2025.

2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

Massari F, Mollica V, Kopp RM, et al. Eur Urol Focus. 2025;11(5):736-746.

2025
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis

Marchetti A, Mollica V, Farolfi A, et al. Clin Genitourin Cancer. 2025;23(5):102406.

2025
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma

Tateo V, Ricci C, Melotti S, et al. Clin Genitourin Cancer. 2025;23(6):102444.

2025
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years?

Danielli L, Rosellini M, Tassinari E, et al. Expert Opin Investig Drugs. Published online December 19, 2025.

2024
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial

Rosellini M, Tassinari E, Marchetti A, et al. Eur Urol. 2024;85(1):97-98.

2024
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?

Tassinari E, Rosellini M, Marchetti A, et al. Expert Opin Drug Metab Toxicol. 2024 Feb 1:1-4

2024
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report

Casadio C, Tassinari E, Carloni C, et al. Case Rep Oncol. 2024 Feb 15;17(1):264-270

2024
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis

Rosellini M, Mollica V, Marchetti A, et al. Pathol Res Pract. 2024 Feb;254:155142.

2024
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?

Conci N, Tassinari E, Tateo V, et al. Mol Diagn Ther. 2024 Jan;28(1):37-51.

2024

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab

Mollica V, Tassinari E, Santoni M, et al. Pathol Res Pract. 2024 Jan;253:155008.

2024

Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma

Mollica V, Rosellini M, Brocchi S, et al. Expert Rev Precis Med Drug Dev. 2024 Mar;9:1,17-24.

2024

Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?

Rosellini M, Marchetti A, Tassinari E, et al.Expert Opin Biol Ther. 2024;24(6): 411-414.

2024

Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives

Compagno S, Casadio C, Galvani L, et al. J Clin Med. 2024;13(19):5738.

2024

A prospective study on the early evaluation of response to androgen receptortargeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience

Mollica V, Marchetti A, Fraccascia N, et al. ESMO Open. 2024;9(5):103448.

2023

An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma

Rosellini M, Tassinari E, Marchetti A, et al. Expert Opin Drug Saf. 2023 Apr;22(4):279-291.

2023

Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

Scrivi qui la descrizione...

Santoni M, Rizzo A, Kucharz J, et al. Cancer Immunol Immunother. 2023;72(6):1365-1379.

2023

Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer

Rosellini M, Marchetti A, Tassinari E, et al. Expert Rev Precis Med Drug Dev. 2023;7:1, 131-149.

2023

Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.

Rizzo A, Mollica V, Tateo V, et al. Cancer Immunol Immunother. 2023;72(6):1381-1394.

2023

Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis.

Rizzo A, Nuvola G, Palmiotti G, et al. Immunotherapy. 2023;15(2):117-126.

2023

The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study

Mollica V, Rizzo A, Marchetti A, et al. Clin Exp Med. 2023;10.1007/s10238-023-01159-1.

2023
Prostate cancer and novel pharmacological treatment options-what's new for 2022?.

Marchetti A, Tassinari E, Rosellini M, et al. Expert Rev Clin Pharmacol. 2023;16(3):231-244.

2023
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report

Tassinari E, Conci N, Battisti G, et al. Front Oncol. 2023 Dec 20;13:1310452.

2022
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?

Marchetti A, Rosellini M, Mollica V, et al Int J Mol Sci. 2021;22(12):6237.

2022
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.

Tassinari E, Mollica V, Nuvola G, et al. Cancer Manag Res. 2022;14:1945-1960.

2022
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study.

Rizzo A, Mollica V, Marchetti A, et al. Cancers (Basel). 2022;14(17):4142.

2022
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.

Mollica V, Nuvola G, Tassinari E, et al. Curr Oncol. 2022;29(3):1709-1722.

2022
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?

Marchetti A, Rosellini M, Nuvola G, et al. Cancers (Basel). 2022;14(4):907.

2022
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis.

Mollica V, Massari F, Andrini E, et al. Curr Oncol. 2022;29(8):5846-5854.

2022
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.

Marchese PV, Mollica V, De Biase D, et al. Pathol Res Pract. 2022;236:153983.

2022
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy

Aggiungi una descrizione qui...

De Giglio A, Tassinari E, Zappi A et al. Cancers. 2022;14(23):5845.

2022
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.

Marchese PV, Mollica V, Tassinari E, et al. Expert Rev Mol Diagn. 2022;22(11):997-1008.

2021
Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.

Mollica V, Rizzo A, Tassinari E, et al. Anticancer Drugs. 2021;32(1):74-81.

ABSTRACTS

An Italian multicenter retrospective study exploring the real-world use of erdafitinib in previously treated metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR) 2/3 alterations

International Urology Cancer Summit, Portsmouth (UK), 3-4 Sep 2025

Mini-Oral Session, Abstract Code: IUC24392-85

A. Dri, A. Polymeropoulos, E. Lai, F. Pierantoni, M. Ghidini, A. Mennitto, A. Zivi, E. Tassinari, R. Cengarle, L. Fratino

Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis

ESMO Immuno-Oncology Annual Congress, Geneva, 6-8 Dic 2023

Poster Display, 24P

Matteo Rosellini, Veronica Mollica, Sara Coluccelli, Francesca Giunchi, Costantino Ricci, Andrea Marchetti, **Elisa Tassinari**, Michelangelo Fiorentino, Dario De Biase, Francesco Massari

A hypothesis generating analysis of the role of chromosome 3p-related genes as predictors for immunocombinations in metastatic renal cell carcinoma (mRCC)

EMUC23, Marseille, 2-5 Nov 2023

Poster Session, P153

Matteo Rosellini, Veronica Mollica, Sara Coluccelli, Francesca Giunchi, Costantino Ricci, Andrea Marchetti, **Elisa Tassinari**, Michelangelo Fiorentino, Dario De Biase, Francesco Massari

Telomerase reverse transcriptase promoter (TERTp) mutations as potential biomarker in patients (pts) with advanced urothelial carcinoma (aUC).

XXV National Congress AIOM, Rome, 10-12 Nov 2023

Poster Session, A19

Elisa Tassinari, Veronica Mollica, Francesca Giunchi, Paola Valeria Marchese, Thais Maloberto, Valentina Tateo, Costantino Ricci, Matteo Rosellini, Andrea Marchetti, Michelangelo Fiorentino, Dario De Biase, Francesco Massari.

A prospective study on the utility of PET/CT in the early evaluation of response to androgen receptor targeted agents (ARTA) in metastatic castration-resistant prostate cancer (mCRPC).

XXV National Congress AIOM, Rome, 10-12 Nov 2023

Poster Session, A36

Andrea Marchetti, Veronica Mollica, Matteo Rosellini, **Elisa Tassinari**, Elena Tabacchi, Alexandro Paccapelo, Valentina Tateo, Strefano Fanti, Francesco Massari.

Evaluation of response to pembrolizumab plus axitinib with tumor growth rate (TGR)in patients (pts) with metastatic renal cell carcinoma (mRCC).

XXV National Congress AIOM, Rome, 10-12 Nov 2023

Poster Session, A46

Matteo Rosellini, Veronica Mollica, Stefano Brocchi, Francesco Galuppi, Alexandro Paccapelo, Andrea Marchetti, **Elisa Tassinari**, Valentina Tateo, Matteo Santoni, Francesco Massari.

A hypothesis generating analysis on the Role Of Tert Promoter Mutation In Advanced Urothelial Carcinoma Treated With Immunotherapy.

XXIV National Congress AIOM, Rome, 01-03 Oct 2022

Poster Session, D13

Paola Valeria Marchese, Veronica Mollica, Dario De Biase, Francesca Giunchi, Giacomo Nuvola, Andrea Marchetti, Matteo Rosellini, **Elisa Tassinari**, Michelangelo Fiorentino, Francesco Massari.

Multidisciplinary Unit for the Management of Urothelial Carcinoma

XXXII National Congress SIUrO, Florence, 6-8 Oct 2022

Abstract 43

Veronica Mollica, Francesco Chessa, Francesco Massari, Giacomo Nuvola, Andrea Marchetti, Matteo Rosellini, **Elisa Tassinari**, Riccardo Schiavina, Eugenio Brunocilla.

A hypothesis generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy

XXXII National Congress SIUrO, Florence, 6-8 Oct 2022

Oral presentation at "Presidential Symposium" (abstract 41)

Paola Valeria Marchese, Veronica Mollica, Dario De Biase, Francesca Giunchi, Giacomo Nuvola, Andrea Marchetti, Matteo Rosellini, **Elisa Tassinari**, Michelangelo Fiorentino, Francesco Massari.

Approcci combinati nella gestione della nausea e del vomito nel setting delle Cure Palliative: un caso clinico.

XXX National Congress of Italian Society of Palliative Care, Riccione, 16-18 Nov 2023

E-presentation - n 124575

Chiara Casadio, Elisa Tassinari, Riccardo Carloni, Romina Rossi, Maria Valentina Tenti, Laura Fabbri, Marco Cesare Maltoni

I hereby authorize the processing of my personal data included in this CV in accordance with Regulation (EU) 2016/679 (General Data Protection Regulation – GDPR).

Meldola , 19/06/2026



Elisa Tassinari